MIP-4 (PARC), human recombinant protein
Small inducible cytokine A18, CCL18, Macrophage inflammatory protein 4, MIP-4, pulmonary and activat
|Calculated MW||7.8 kDa|
|Other Names||Small inducible cytokine A18, CCL18, Macrophage inflammatory protein 4, MIP-4, pulmonary and activation-regulated chemokine, CC chemokine PARC, Alternative macrophage activation-associated CC chemokine 1, AMAC-1, Dendritic cell chemokine 1, DC-CK1, chemokine (C-C motif) ligand 18, CKb7, PARC, AMAC1, DCCK1, SCYA18,|
|Application Notes||Reconstitute in H₂O to a concentration of 1 mg/ml. The solution can be diluted into other buffered solutions|
|Storage||-20°C; Sterile filtered and lyophilized with no additives|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Human microphage inflammatory protein-4 (MIP-4) also known as PARC, has been shown to be chemotactic for T lymphocytes but not for monocytes or granulocytes. BioVision’s human MIP-4 is an 7.8 kDa protein containing 68 amino acid residues.
Li H.,et al.Patent number US5504003, 02-APR-1996.
Hieshima K.,et al.J. Immunol. 159:1140-1149(1997).
Kodelja V.,et al.J. Immunol. 160:1411-1418(1998).
Adema G.J.,et al.Nature 387:713-717(1997).
Tasaki Y.,et al.Genomics 55:353-357(1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.